BioCentury | Apr 10, 2020
Product Development

April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge

...a Phase IIa trial to treat ulcerative colitis. The interim analysis showed that the first-in-class PELI1...
...cell death 1 CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 PELI1 (pellino-1) - Pellino E3 ubiquitin protein ligase 1 BioCentury...
...Yervoy (Other) Liquidia Technologies Inc. Bridge Biotherapeutics Inc. AstraZeneca plc Circassia Pharmaceuticals plc Bristol Myers Squibb Co. Merck & Co. Inc. Pfizer Inc. Pellino E3 ubiquitin protein ligase 1 (PELI1) (pellino-1)...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

Eleven COVID-19 patients discharged after receiving Ascletis drug Ascletis Pharma Inc. (HKEX:1672) said all 11 COVID-19 patients in a cohort receiving Ganovo danoprevir plus ritonavir in a Chinese Phase IV trial have been discharged from...
BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...expects data from a Phase IIa trial of BBT-401, a first-in-class small molecule inhibitor of PELI1...
...EGFR (ErbB1; HER1) - Epidermal growth factor receptor ENPP2 (ATX) - Autotaxin PELI1 (pellino-1) - Pellino E3 ubiquitin protein ligase 1 Stephen...
BioCentury | Jul 18, 2019
Company News

Boehringer deal enables Bridge to expand pipeline, take in-house programs further

...in Phase II testing for ulcerative colitis. Targets: ENPP2 (ATX) - autotaxin; PELI1 (pellino-1) - pellino E3 ubiquitin protein ligase 1...
BioCentury | Apr 1, 2019
Financial News

Bridge raises $27.2M series C led by UTC, Shinhan

...months and support completion of a Phase IIa trial of the small molecule inhibitor of PELI1...
...fibrotic disease candidate BBT-887, an ENPP2 inhibitor. Targets: ENPP2 (ATX) - Autotaxin; PELI1 (pellino-1) - Pellino E3 ubiquitin protein ligase 1 Mark...
BioCentury | Dec 21, 2018
Company News

Bridge, Daewoong partner on BBT-401 for ulcerative colitis

...will receive exclusive rights to develop and commercialize the small molecule inhibitor of pellino E3 ubiquitin protein ligase 1 (PELI1; pellino-1...
...Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Korea Business: Autoimmune Sandi Wong BBT-401 Bridge Biotherapeutics Inc. Daewoong Pharmaceutical Co. Ltd. Pellino E3 ubiquitin protein ligase 1 (PELI1) (pellino-1) Autoimmune...
BioCentury | Nov 16, 2018
Clinical News

Bridge's ulcerative colitis candidate headed for Phase II

...BBT-401 in patients with ulcerative colitis. BBT-401 is a small molecule inhibitor of pellino E3 ubiquitin protein ligase 1 (PELI1; pellino-1...
...Korea Product: BBT-401 Business: Autoimmune Molecular target: Pellino E3 ubiquitin protein ligase 1 (PELI1; pellino-1) Description: Small molecule inhibitor of PELI1...
...colitis Endpoint: Safety; pharmacokinetics Status: Phase I data Milestone: Start Phase II (12/2018) Sandi Wong BBT-401 Bridge Biotherapeutics Inc. Pellino E3 ubiquitin protein ligase 1 (PELI1) (pellino-1)...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

...biotechs. Lead program BBT-401 is an N-terminal lipidated 4aa peptide targeting pellino E3 ubiquitin protein ligase 1 ( PELI1 ; pellino-1...
...testing for inflammatory diseases. Lee told BioCentury he is unaware of any other programs targeting pellino-1...
BioCentury | Oct 10, 2016
Emerging Company Profile

Pellino play

...pellino-1 ). Bridge exclusively licensed IP covering BBT-401, its derivatives and therapeutic uses related to pellino-1...
...milestones and royalties. CEO James Lee said in conditions such as inflammatory bowel disease (IBD), pellino-1...
...is that pellino-1 mediates TLR adaptor molecule 1 ( TICAM1 ; TRIF )-dependent signaling. Inhibiting pellino-1...
BioCentury | May 8, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer VEGF-A In vitro and mouse studies suggest hepatocellular carcinoma (HCC) with amplifications in VEGF-A may be particularly susceptible to Nexavar sorafenib. In mice...
Items per page:
1 - 10 of 11